Therapeutic effect of high-flux hemodialysis combined with hemoperfusion on patients with end stage renal disease

Lin Bin Dou; Wei Ming Zhang; Yong Mei Wang; Xing Hui Lin; Hong Cai; Yi Jun Zhou; Ming Li Zhu; Yu Cheng Yan; Zhao Hui Ni; Jia Qi Qian

doi:10.3969/j.issn.1674-8115.2015.09.020

Therapeutic effect of high-flux hemodialysis combined with hemoperfusion on patients with end stage renal disease

Lin Bin Dou, Wei Ming Zhang, Yong Mei Wang, Xing Hui Lin, Hong Cai, Yi Jun Zhou, Ming Li Zhu, Yu Cheng Yan, Zhao Hui Ni, Jia Qi Qian

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

Objective: To investigate the effects of combination of high-flux hemodialysis (HFD) with hemoperfusion (HP) on the removal of middle and large molecule solutes such as serum fibroblast growth factor 23 (FGF23) and interleukin 6 (IL-6) and the improvement of life quality of patients undergoing maintenance hemodialysis (MHD). Methods: A total of 35 MHD patients were enrolled and underwent two HFD and one HFD+HP per week for 12 months. Indexes such as serum albumin, hemoglobin, phosphorus, calcium, and intact parathyroid hormone (iPTH) were measured every 3 months. Serum FGF23 and IL-6 were detected by ELISA in 0, 6, and 12 months. SF-36 scale was used to evaluate the life quality of patients at the beginning and end of study. Results: A total of 33 patients were followed up for 12 months. The mean age was (59.06±0.64) years and mean dialysis vintage was (178.94±51.50) months. Hemoglobin, pre-albumin, albumin, calcium, phosphorus, and iPTH of patients during follow-up were not significantly different from those before treatment. FGF23 decreased remarkably after being treated for 6 months (P=0.046) and decreased continuously after being treated for 12 months (P=0.006). IL-6 decreased remarkably after being treated for 6 months (P=0.015) and decreased continuously after being treated for 12 months (P=0.015). Scores of all items of MHD patients improved significantly after being followed up for 12 months (P<0.05). Conclusion: HFD+HP can efficiently remove middle and large molecule toxins and is an effect treatment for improving the life quality of MHD patients.

Original language	English
Pages (from-to)	1344-1349
Number of pages	6
Journal	Journal of Shanghai Jiaotong University (Medical Science)
Volume	35
Issue number	9
DOIs	https://doi.org/10.3969/j.issn.1674-8115.2015.09.020
State	Published - 28 Sep 2015
Externally published	Yes

Keywords

Fibroblast growth factor 23
Hemodialysis
Hemoperfusion
Interleukin 6
Quality of life

Access to Document

10.3969/j.issn.1674-8115.2015.09.020

Cite this

Dou, L. B., Zhang, W. M., Wang, Y. M., Lin, X. H., Cai, H., Zhou, Y. J., Zhu, M. L., Yan, Y. C., Ni, Z. H., & Qian, J. Q. (2015). Therapeutic effect of high-flux hemodialysis combined with hemoperfusion on patients with end stage renal disease. Journal of Shanghai Jiaotong University (Medical Science), 35(9), 1344-1349. https://doi.org/10.3969/j.issn.1674-8115.2015.09.020

@article{1427958e665c45628c24e1bcff524652,

title = "Therapeutic effect of high-flux hemodialysis combined with hemoperfusion on patients with end stage renal disease",

abstract = "Objective: To investigate the effects of combination of high-flux hemodialysis (HFD) with hemoperfusion (HP) on the removal of middle and large molecule solutes such as serum fibroblast growth factor 23 (FGF23) and interleukin 6 (IL-6) and the improvement of life quality of patients undergoing maintenance hemodialysis (MHD). Methods: A total of 35 MHD patients were enrolled and underwent two HFD and one HFD+HP per week for 12 months. Indexes such as serum albumin, hemoglobin, phosphorus, calcium, and intact parathyroid hormone (iPTH) were measured every 3 months. Serum FGF23 and IL-6 were detected by ELISA in 0, 6, and 12 months. SF-36 scale was used to evaluate the life quality of patients at the beginning and end of study. Results: A total of 33 patients were followed up for 12 months. The mean age was (59.06±0.64) years and mean dialysis vintage was (178.94±51.50) months. Hemoglobin, pre-albumin, albumin, calcium, phosphorus, and iPTH of patients during follow-up were not significantly different from those before treatment. FGF23 decreased remarkably after being treated for 6 months (P=0.046) and decreased continuously after being treated for 12 months (P=0.006). IL-6 decreased remarkably after being treated for 6 months (P=0.015) and decreased continuously after being treated for 12 months (P=0.015). Scores of all items of MHD patients improved significantly after being followed up for 12 months (P<0.05). Conclusion: HFD+HP can efficiently remove middle and large molecule toxins and is an effect treatment for improving the life quality of MHD patients.",

keywords = "Fibroblast growth factor 23, Hemodialysis, Hemoperfusion, Interleukin 6, Quality of life",

author = "Dou, {Lin Bin} and Zhang, {Wei Ming} and Wang, {Yong Mei} and Lin, {Xing Hui} and Hong Cai and Zhou, {Yi Jun} and Zhu, {Ming Li} and Yan, {Yu Cheng} and Ni, {Zhao Hui} and Qian, {Jia Qi}",

year = "2015",

month = sep,

day = "28",

doi = "10.3969/j.issn.1674-8115.2015.09.020",

language = "English",

volume = "35",

pages = "1344--1349",

journal = "Journal of Shanghai Jiaotong University (Medical Science)",

issn = "1674-8115",

publisher = "Editorial Department of Journal of Shanghai Second Medical University",

number = "9",

}

TY - JOUR

T1 - Therapeutic effect of high-flux hemodialysis combined with hemoperfusion on patients with end stage renal disease

AU - Dou, Lin Bin

AU - Zhang, Wei Ming

AU - Wang, Yong Mei

AU - Lin, Xing Hui

AU - Cai, Hong

AU - Zhou, Yi Jun

AU - Zhu, Ming Li

AU - Yan, Yu Cheng

AU - Ni, Zhao Hui

AU - Qian, Jia Qi

PY - 2015/9/28

Y1 - 2015/9/28

N2 - Objective: To investigate the effects of combination of high-flux hemodialysis (HFD) with hemoperfusion (HP) on the removal of middle and large molecule solutes such as serum fibroblast growth factor 23 (FGF23) and interleukin 6 (IL-6) and the improvement of life quality of patients undergoing maintenance hemodialysis (MHD). Methods: A total of 35 MHD patients were enrolled and underwent two HFD and one HFD+HP per week for 12 months. Indexes such as serum albumin, hemoglobin, phosphorus, calcium, and intact parathyroid hormone (iPTH) were measured every 3 months. Serum FGF23 and IL-6 were detected by ELISA in 0, 6, and 12 months. SF-36 scale was used to evaluate the life quality of patients at the beginning and end of study. Results: A total of 33 patients were followed up for 12 months. The mean age was (59.06±0.64) years and mean dialysis vintage was (178.94±51.50) months. Hemoglobin, pre-albumin, albumin, calcium, phosphorus, and iPTH of patients during follow-up were not significantly different from those before treatment. FGF23 decreased remarkably after being treated for 6 months (P=0.046) and decreased continuously after being treated for 12 months (P=0.006). IL-6 decreased remarkably after being treated for 6 months (P=0.015) and decreased continuously after being treated for 12 months (P=0.015). Scores of all items of MHD patients improved significantly after being followed up for 12 months (P<0.05). Conclusion: HFD+HP can efficiently remove middle and large molecule toxins and is an effect treatment for improving the life quality of MHD patients.

AB - Objective: To investigate the effects of combination of high-flux hemodialysis (HFD) with hemoperfusion (HP) on the removal of middle and large molecule solutes such as serum fibroblast growth factor 23 (FGF23) and interleukin 6 (IL-6) and the improvement of life quality of patients undergoing maintenance hemodialysis (MHD). Methods: A total of 35 MHD patients were enrolled and underwent two HFD and one HFD+HP per week for 12 months. Indexes such as serum albumin, hemoglobin, phosphorus, calcium, and intact parathyroid hormone (iPTH) were measured every 3 months. Serum FGF23 and IL-6 were detected by ELISA in 0, 6, and 12 months. SF-36 scale was used to evaluate the life quality of patients at the beginning and end of study. Results: A total of 33 patients were followed up for 12 months. The mean age was (59.06±0.64) years and mean dialysis vintage was (178.94±51.50) months. Hemoglobin, pre-albumin, albumin, calcium, phosphorus, and iPTH of patients during follow-up were not significantly different from those before treatment. FGF23 decreased remarkably after being treated for 6 months (P=0.046) and decreased continuously after being treated for 12 months (P=0.006). IL-6 decreased remarkably after being treated for 6 months (P=0.015) and decreased continuously after being treated for 12 months (P=0.015). Scores of all items of MHD patients improved significantly after being followed up for 12 months (P<0.05). Conclusion: HFD+HP can efficiently remove middle and large molecule toxins and is an effect treatment for improving the life quality of MHD patients.

KW - Fibroblast growth factor 23

KW - Hemodialysis

KW - Hemoperfusion

KW - Interleukin 6

KW - Quality of life

UR - http://www.scopus.com/inward/record.url?scp=84947547259&partnerID=8YFLogxK

U2 - 10.3969/j.issn.1674-8115.2015.09.020

DO - 10.3969/j.issn.1674-8115.2015.09.020

M3 - Article

AN - SCOPUS:84947547259

SN - 1674-8115

VL - 35

SP - 1344

EP - 1349

JO - Journal of Shanghai Jiaotong University (Medical Science)

JF - Journal of Shanghai Jiaotong University (Medical Science)

IS - 9

ER -

Therapeutic effect of high-flux hemodialysis combined with hemoperfusion on patients with end stage renal disease

Abstract

Keywords

Access to Document

Fingerprint

Cite this